Most natural senescence remedies for artery plaque fail a strict test, and only quercetin and fisetin pass
A new review applies a strict senolytic definition to five natural compounds for artery plaque. Only quercetin and fisetin qualify, and human data are thin.
Summary
Aging blood vessels accumulate senescent cells, which stop dividing and release inflammatory signals known as the SASP. This review explains how those signals inflame artery plaque, thin the protective fibrous cap, and raise rupture risk. The authors then test five popular natural compounds (tetramethylpyrazine, quercetin, fisetin, resveratrol and curcumin) against a strict definition requiring effects in confirmed senescent cells. Only quercetin and fisetin pass. The rest mainly reduce inflammation or oxidative stress. Human evidence is very limited: quercetin improved blood vessel relaxation in tissue from male, but not female, bypass patients in the lab. The authors conclude that targeting the SASP is promising but still needs clinical trials, not supplement shortcuts.
Detailed Summary
Atherosclerosis drives most heart attacks and ischemic strokes, and age is its strongest nonmodifiable risk factor. This narrative review argues that cellular senescence, the irreversible cell-cycle arrest that accumulates with age, helps explain why. Senescent cells do not simply sit idle. They secrete the senescence-associated secretory phenotype (SASP), a mix of cytokines, chemokines, proteases and procoagulant factors that spreads inflammation and can push neighboring healthy cells into senescence. The authors stress that most causal evidence is still preclinical.
The review describes three senescent cell populations in plaques. Endothelial cells show high p16INK4a and p21CIP1, produce less nitric oxide, and express adhesion molecules such as VCAM-1 and ICAM-1 that capture monocytes. Smooth muscle cells make less collagen and more MMP-2, MMP-9 and MMP-13, thinning the fibrous cap. Senescent macrophages and foam cells have defective efferocytosis and keep releasing IL-1β, IL-6 and TNF-α, which feeds necrotic-core inflammation. Together these changes favor thin-cap fibroatheromas, the plaque type most likely to rupture.
Mechanistically, the SASP is maintained by several linked pathways. DNA damage signaling through ATM and ATR activates NF-κB, the master SASP switch, and cytosolic DNA activates cGAS–STING. p38 MAPK amplifies and stabilizes SASP transcripts. mTORC1 supports the heavy protein synthesis the SASP requires, so rapamycin suppresses secretion without killing cells, which makes it senomorphic rather than senolytic. The NLRP3 inflammasome matures IL-1β in macrophages exposed to cholesterol crystals. Importantly, blocking NF-κB reduces SASP output without reversing growth arrest.
The clearance evidence is mixed. In LDLR−/− INK-ATTAC mice, eliminating p16-expressing cells reduced inflammatory markers and necrotic core size and increased fibrous-cap thickness. Dasatinib plus quercetin improved vascular function in aged and atherosclerotic mice. However, in atherosclerotic mice the clearance was restricted to the medial layer and did not reduce lesion size. In humans, the CANTOS trial showed that IL-1β blockade with canakinumab lowered recurrent cardiovascular events, but no such agent has been tested against a senescence-specific endpoint.
The authors then evaluate tetramethylpyrazine (ligustrazine), quercetin, fisetin, resveratrol and curcumin. They reserve the terms senolytic and senomorphic for effects shown in confirmed senescent cells. By that standard only quercetin and fisetin qualify. For the other three, the vascular data show anti-inflammatory, antioxidant or senescence-preventive effects. Tetramethylpyrazine protects the endothelial glycocalyx and reduces plaque area in atherosclerotic rabbits. The only human data come from quercetin monotherapy, which improved endothelium-dependent vasodilation ex vivo in vessels from symptomatic male, but not female, bypass patients.
The authors also discuss how multiomics profiling and biomarkers could eventually stratify patients by senescence burden for personalized senotherapy. They are cautious about how far the evidence goes. Much of it comes from cells never shown to be senescent, and no formulation has been shown to reach the human vessel wall. The paper is a nonsystematic narrative review with purposive study selection and no risk-of-bias assessment. Its conclusion is that SASP-targeting needs trial evidence before it can anchor precision cardiovascular medicine.
Key Findings
- Only 2 of 5 natural compounds reviewed (quercetin and fisetin) meet the strict senolytic/senomorphic definition requiring effects in confirmed senescent cells
- Tetramethylpyrazine protected the endothelial glycocalyx and reduced plaque area in atherosclerotic rabbits, but this is anti-inflammatory rather than proven senolytic evidence
- Genetic clearance of p16-expressing cells in LDLR−/− INK-ATTAC mice reduced necrotic core size and increased fibrous-cap thickness
- Dasatinib plus quercetin improved vascular function in mice, but in atherosclerotic mice clearance was limited to the medial layer and did not shrink lesions
- The only human evidence is ex vivo: quercetin improved endothelium-dependent vasodilation in vessels from symptomatic male, but not female, bypass patients
- CANTOS showed IL-1β inhibition with canakinumab lowered recurrent cardiovascular events, but no such agent has been tested against a senescence-specific endpoint
- SASP is sustained through NF-κB, p38 MAPK, mTOR, NLRP3 and cGAS–STING; NF-κB inhibition cuts SASP output without reversing growth arrest
Methodology
This is a narrative, nonsystematic review. The authors searched PubMed/MEDLINE and Web of Science from inception through June 2026, using combined terms for senescence/SASP, atherosclerosis cell types, and natural products. English-language studies were selected purposively for mechanistic relevance, with preference for primary data where evidence conflicted. No eligibility grid, duplicate screening, PRISMA flow diagram, or risk-of-bias assessment was applied, and no pooled statistics were generated.
Study Limitations
The authors acknowledge that the causal evidence is largely preclinical and that much of the natural product data came from cells never confirmed as senescent. Human cardiovascular interventional data are minimal, and spatial mapping of senescence in human plaques is lacking. The narrative design with purposive selection carries risk of selection bias. No conflict-of-interest information was included in the text provided.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe:
